Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) major shareholder Philip R. Harper bought 20,470 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were purchased at an average price of $1.19 per share, with a total value of $24,359.30. Following the transaction, the insider now owns 4,865,683 shares of the company’s stock, valued at $5,790,162.77. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Aevi Genomic Medicine, Inc. (GNMX) traded up 5.70% during midday trading on Monday, reaching $1.39. The company had a trading volume of 298,133 shares. Aevi Genomic Medicine, Inc. has a 12-month low of $0.98 and a 12-month high of $6.89. The stock has a 50-day moving average price of $1.28 and a 200 day moving average price of $2.40. The company’s market capitalization is $51.58 million.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/14/aevi-genomic-medicine-inc-nasdaqgnmx-major-shareholder-philip-r-harper-buys-20470-shares.html.

Hedge funds have recently modified their holdings of the stock. Teachers Advisors LLC purchased a new stake in shares of Aevi Genomic Medicine during the fourth quarter worth approximately $204,000. State Street Corp raised its stake in shares of Aevi Genomic Medicine by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the biotechnology company’s stock worth $1,789,000 after buying an additional 46,149 shares during the last quarter. Northern Capital Management LLC raised its stake in shares of Aevi Genomic Medicine by 317.9% in the second quarter. Northern Capital Management LLC now owns 106,050 shares of the biotechnology company’s stock worth $141,000 after buying an additional 80,675 shares during the last quarter. Birchview Capital LP raised its stake in shares of Aevi Genomic Medicine by 88.2% in the second quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock worth $170,000 after buying an additional 60,000 shares during the last quarter. Finally, LMR Partners LLP purchased a new stake in shares of Aevi Genomic Medicine during the second quarter worth approximately $149,000. 27.96% of the stock is owned by institutional investors and hedge funds.

GNMX has been the subject of a number of recent analyst reports. UBS AG reiterated a “positive” rating on shares of Aevi Genomic Medicine in a report on Wednesday, May 10th. Jefferies Group LLC reiterated a “hold” rating and issued a $1.50 price objective on shares of Aevi Genomic Medicine in a report on Monday, August 7th. Finally, ValuEngine downgraded Aevi Genomic Medicine from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease.

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.